Acquired Resistance to Therapy Network (ARTNet; U54 Clinical Trial Not Allowed)

Funding Opportunity RFA-CA-21-052 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) is inviting applications to form the Acquired Resistance to Therapy Network (ARTNet). The ARTNet FOA is a reissuance that builds upon the Drug Resistance and Sensitivity Network (DRSN, RFA-CA-17-009) to focus study on the mechanistic basis of acquired resistance to cancer therapies and disease recurrence. Central to the ARTNets structural organization is team science approaches that iteratively bridge basic, pre-clinical, and translational research along the tumor-microenvironment continuum to inform new strategies that can be better translated to overcome significant challenges in acquired resistance to cancer therapies. This FOA will be published in parallel with a companion FOA titled Coordinating and Data Management Center (CDMC) for Acquired Resistance to Therapy Network (ARTNet; U24 Clinical Trial Not Allowed).
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding